Could Aclaris Therapeutics Inc (NASDAQ:ACRS) Change Direction After Less Shorts?

April 17, 2018 - By Hazel Jackson

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Logo

The stock of Aclaris Therapeutics Inc (NASDAQ:ACRS) registered a decrease of 4.86% in short interest. ACRS’s total short interest was 5.01M shares in April as published by FINRA. Its down 4.86% from 5.27M shares, reported previously. With 290,300 shares average volume, it will take short sellers 17 days to cover their ACRS’s short positions. The short interest to Aclaris Therapeutics Inc’s float is 19.8%.

The stock increased 0.91% or $0.16 during the last trading session, reaching $17.78. About 183,844 shares traded. Aclaris Therapeutics, Inc. (NASDAQ:ACRS) has declined 45.27% since April 17, 2017 and is downtrending. It has underperformed by 56.82% the S&P500.

Aclaris Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing topical drugs to address various unmet needs in dermatology. The company has market cap of $549.43 million. The Company’s lead drug candidate is A-101, a hydrogen peroxide topical solution, which is in Phase III clinical trials for the treatment of seborrheic keratosis , a common non-malignant skin tumor. It currently has negative earnings. The firm is also developing A-101 as a prescription treatment for common warts.

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.